The health burden of primary biliary cholangitis in Switzerland: a cross-sectional study

Beretta-Piccoli, Benedetta C.; Stirnimann, Guido; Cerny, Andreas; Bakker, Carolina Khalid-de; Semela, David; Hessler, Roxane; Giostra, Emiliano; Helbling, Beat; Stickel, Felix; Bihl, Florian; Invernizzi, Pietro; Mertens, Jessica; Carbone, Matteo Domenico

doi:10.1016/s0168-8278(17)31053-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary biliary cirrhosis (PBC) is clinically a type of autoimmune cholestatic liver disease characterized by serum autoantibody antimitochondrial antibodies (AMAs) (1,2), chronic progressive cholestasis, interlobular bile duct damage, liver inflammation, eventual cirrhosis, and death (3,4). Studies have found that the incidence and prevalence of PBC have increased globally in the past few decades (5,6), especially among women (7).…”

Section: Introductionmentioning

confidence: 99%

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

et al. 2023

View full text Add to dashboard Cite

Primary biliary cirrhosis (PBC) is a chronic cholestatic immune liver disease characterized by persistent cholestasis, interlobular bile duct damage, portal inflammation, liver fibrosis, eventual cirrhosis, and death. Existing clinical and animal studies have made a good progress in bile acid metabolism, intestinal flora disorder inflammatory response, bile duct cell damage, and autoimmune response mechanisms. However, the pathogenesis of PBC has not been clearly elucidated. We focus on the pathological mechanism and new drug research and development of PBC in clinical and laboratory in the recent 20 years, to discuss the latest understanding of the pathological mechanism, treatment options, and drug discovery of PBC. Current clinical treatment mode and symptomatic drug support obviously cannot meet the urgent demand of patients with PBC, especially for the patients who do not respond to the current treatment drugs. New treatment methods are urgently needed. Drug candidates targeting reported targets or signals of PBC are emerging, albeit with some success and some failure. Single-target drugs cannot achieve ideal clinical efficacy. Multitarget drugs are the trend of future research and development of PBC drugs.

show abstract